PFKL: A Protein Regulator of The Immune System (G5211)

Target Name: PFKL

NCBI ID: G5211

PFKL

PFKL: A Protein Regulator of The Immune System

PFKL (Proteasome-Mediated degradation of Light Chain) is a protein that plays a critical role in the regulation of the humoral immune response. It is a 24 kDa protein that is composed of two light chains and a 15 kDa protein core. PFKL is expressed in a variety of tissues, including spleen, thymus, and Peyer's patches, and is involved in the degradation of light chains from immune complexes.

PFKL is a key regulator of the B cell maturation and activation process. During B cell development, PFKL helps to ensure that only mature B cells are activated and that these cells are able to undergo clonal expansion and differentiate into antibody-secreting plasma cells. PFKL also plays a role in regulating the expression of other immune cell genes, including those involved in cell death and apoptosis.

In addition to its role in B cell development, PFKL is also involved in the regulation of other immune cell functions. For example, PFKL has been shown to play a role in regulating the activation and proliferation of natural killer cells, and it has been shown to influence the production of cytotoxic T lymphocytes (CTLs) by regulatory T cells.

PFKL is also a potential drug target for several diseases. One of the main targets for PFKL is the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. These diseases are characterized by the overzealous immune system, which leads to the production of antibodies that can cause damage to the body's own tissues. PFKL has been shown to play a role in the regulation of the immune response and has been shown to have anti-inflammatory effects. As a result, PFKL has been targeted by researchers to develop new treatments for autoimmune diseases.

Another potential target for PFKL is the treatment of cancer. PFKL has been shown to play a role in the regulation of cell cycle progression and has been shown to influence the production of pro-tumorigenic cells. As a result, PFKL has been targeted by researchers to develop new treatments for cancer.

In addition to its potential as a drug target, PFKL is also a valuable biomarker for several diseases. For example, PFKL has been shown to be a useful biomarker for monitoring the efficacy of anti-rheumatic medications in rheumatoid arthritis. PFKL levels have also been used as a biomarker for monitoring the effectiveness of cancer treatments.

Overall, PFKL is a complex protein that plays a critical role in the regulation of the immune system. Its role in B cell development and the regulation of other immune cell functions makes it an attractive target for research and treatment of a variety of diseases. As A potential drug target and biomarker, PFKL is a promising area of 鈥嬧?媟esearch for the future.

Protein Name: Phosphofructokinase, Liver Type

Functions: Catalyzes the phosphorylation of D-fructose 6-phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis (PubMed:22923583). Negatively regulates the phagocyte oxidative burst in response to bacterial infection by controlling cellular NADPH biosynthesis and NADPH oxidase-derived reactive oxygen species. Upon macrophage activation, drives the metabolic switch toward glycolysis, thus preventing glucose turnover that produces NADPH via pentose phosphate pathway (By similarity)

The "PFKL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PFKL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets